Head-to-head evidence
AZD3759 vs Lazertinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
AZD3759
Developed by AstraZeneca and partners
NCT03653546 · Phase 2/3 · completed
The trial randomized 492 participants to AZD3759 or active treatment with erlotinib or gefitinib, with progression-free survival assessed by independent central radiology as the primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: April 2028 · NCT07361705 (registry estimate)
Lazertinib
Marketed by Johnson & Johnson and partners
NCT04248829 · Phase 3 · completed
The trial randomized 393 participants to lazertinib or an active gefitinib control and used quadruple masking, with investigators and outcome assessors blinded. Its primary clinical endpoint, progression-free survival, favored lazertinib numerically, but statistical significance is not reported, so the result cannot be classified as definitively met.
Next expected readout: December 2026 · NCT05463224 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD3759's landscape · Lazertinib's landscape